Skip to Content

'
Edward S. Kim, M. D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Co-Director, Educational Programs, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3016
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1996 Northwestern University, Chicago, IL, MD, Honors Program in Medical Education (HPME)
1992 Northwestern University, Evanston, IL, BS, Systems Biology, Honors Program in Medical Education (HPME: 7 yr Medical Program)

Postgraduate Training

1999-2001 Medical Oncology Fellowship, University of Texas M. D. Anderson Cancer Center, Houston, TX, Waun Ki Hong, M. D., Chairman and Division Head; Robert Wolf, M. D., Fellowship Director
1/1996-1/1999 Clinical Fellowship, Baylor College of Medicine, Houston, TX, Andrew Schafer, M. D., Chairman; Edward Lynch, M. D. Residency Director

Experience/Service

Institutional Committee Activities

Co-Chairman, Committee, Radiation Therapy Oncology Group (RTOG), 2001-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Liao A, Komaki RR, Thames HD, Liu HH, Tucker SL, Mogan R. Martel MK, Wei X, Fossella F, Kim ES, Cox JD. Influence of technological advances on outcomes in patients with unresectable locally advanced non-small cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. In Press.
2. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Ginsberg LE, Truong M, Tran HT, Hong WK, Kim ES. A phase II study of Ionafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. American Journal of Clinical Oncology, 5/2009. PMID: 19433965.
3. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Geng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A Phase II Study of Lonafarnib (SCH66336) in patients with chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol, 5/2009. PMID: 19433965.
4. Gold KA, Lee HY, Kim, ES. Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck. Cancer 1:115(5):922-35, 5/2009. PMID: 19346943.
5. Kim ES, Mauer AM, William Jr. WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase II study of cetuximab in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Cancer 115(8):1713-22, 4/2009. PMID: 19208430.
6. William JR WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting Stage IIIB and IV Non-Small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology and End Results. CHEST. e-Pub 3/2009. PMID: 19318668.
7. William Jr., WN; Lee JL; Shin, DM; Hong, WK, Lee JJ; Lippman SM; Khuri FR, Kim ES. Phase I Trial of Weekly Topotecan and Gemcitabine in Patients with Solid Tumors. American Journal of Clinical Oncology 32(1):15-19, 2/2009. PMID: 19194117.
8. Papadimitrakopoulou VA, Lee JJ, William Jr, WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid versus retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 1(27(4)):599-604, 2/2009. PMID: 19075276.
9. Kim ES, Watkins CL, Armur AA, Douillard JY. Gefitinib plus docetaxel in non-small-cell lung cancer. The Lancet 373 (9663):542, 2009.
10. William Jr., WN, Lippman, Martin JW, Tran HT, Sabichi AL, Kim ES, Feng L, Lee JJ, Papadimitrakopoulou VA. Phase II chemoprevention Trial with High Dose Fenretinide for Oral Pre-Malignant Lesions. Cancer Prevention Research 2:22-26, 2009. PMID: 19139014.
11. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in surviving expression. Clin Cancer Res 14(5):1581-9, 3/2008. PMID: 18316583.
12. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin; a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26(3):354-60, 1/2008.
13. Zhou X, Liu S, Kim ES. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 5(3):181-93, 2008.
14. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu HL, Long-Yun L, Watkins,CL, Sellers MV, Lowe ES, Sun Yan, Liao ML, Osterline K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small cell lung cancer: a randomized phase III trail (INTEREST). The Lancet 273(9652):1809-18, 2008. PMID: 19027483.
15. Bhutani M, Pathank AK, Fan Y-H, Liu D, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prevention Research 1:39-44, 2008. PMID: 19138934.
16. Zheng S, El-Naggar AK, Kim ES, Jurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 26(48):6896-6904, 10/2007. PMID: 17486075.
17. Kim ES, Bosquee L. The importance of accurate lymph node staging in early and locally advanced non-small cell lung cancer; an update on available techniques. J Thorac Oncol Suppl 2S:59-67, 6/2007. PMID: 17589301.
18. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610-621, 5/2007. PMID: 17522250.
19. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 1:13(9)(9). e-Pub 5/2007. PMID: 17473213.
20. Chou LS, Garey J, Oishi K, Kim E. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer 8 Suppl 1:S15-22, 12/2006. PMID: 17239286.
21. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66(20):10100-11, 10/2006. PMID: 17047074.
22. Khuri FR, Lee JJ, Lippman SM, Kim ES, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong RK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. Journal of the National Cancer Institute 98(7):441-450, 4/2006. PMCID: PMC16595780.
23. Kim ES, Johnson ED. Novel combinations with docetaxel in the treatment of non-small-cell lung cancer. Clin Lung Cancer 7 Suppl 3:S83-6, 12/2005. PMID: 16384541.
24. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005. PMID: 16258975.
25. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104(3):561-9, 8/2005. PMID: 16028213.
26. Seixas-Silva, Jr., Jose A., Kim ES. Phase II Bioadjuvant Study of InterferonAlfa-2a, Isotretinoin, and Vitamin E in Local Advanced Squamous Cell Carcinoma of the Head and Neck. American Medical Association. e-Pub 4/2005.
27. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Hypoxia-inducible factor 1a and antiangiogenic activityof farnesyl transferase inhibitor SCH66336 in human aerodigestive tract cancer. Journal of the National Cancer Institute 97 (17):1272-1286, 2005.
28. Lee HY, Kim ES. Implication of hypoxia-inducible factor-1a in antiangiogenic activity of farnesyl transferase inhibitor SCH66336 in human aerodigestive tract cancer. Jrnl Natl Cancer Institute, 2005.

Invited Articles
1. Gold KA, Kim ES. Molecular markers and gene profiling in head and neck cancer. Curr Opin Oncol 21(3):206-11, 5/2009. PMCID: PMC19346943.
2. William Jr, WN, Heymach JV, Kim ES, Lippman SM. Molecular Targets for Cancer Chemotherapy. Nature Reviews Drug Discovery 8(3):213-25, 3/2009. PMID: 19247304.

Editorials
1. William WN, Gold K, Kim ES. gefitinib for advanced non-small cell lung cancer and quality of life: expending and improving treatment options. Annals of Oncology. In Press.
2. William WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. NatClin Pract Oncol 6(3):132-3, 3/2009. e-Pub 1/2009. PMID: 19190590.

Last updated: 8/25/2009